Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions

BACKGROUND: Programmed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developing immune-related adverse events (irAE). Delineat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauché, David, Mauze, Smita, Kochel, Christina, Grein, Jeff, Sawant, Anandi, Zybina, Yulia, Blumenschein, Wendy, Yang, Peng, Annamalai, Lakshmanan, Yearley, Jennifer H, Punnonen, Juha, Bowman, Edward P, Chackerian, Alissa, Laface, Drake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604872/
https://www.ncbi.nlm.nih.gov/pubmed/33127658
http://dx.doi.org/10.1136/jitc-2020-001584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604872/
https://www.ncbi.nlm.nih.gov/pubmed/33127658
http://dx.doi.org/10.1136/jitc-2020-001584

Ejemplares similares